Cantargia (CANTA) investor relations material

Introduction and agenda

• Session focused on IL-1RAP as a therapeutic target in pancreatic cancer and the case for nadunolimab, with an agenda covering disease landscape, IL-1/IL-1RAP biology, clinical data, and strategic positioning.

• KOL call scheduled for June 22, 2026, to discuss IL1RAP as a therapeutic target in pancreatic cancer and the clinical role of nadunolimab.

• Focus on the evolving PDAC treatment landscape and the potential of nadunolimab to complement RAS-directed therapies.

KOL background and credentials

• Dr. Jashodeep Datta is a surgeon scientist specializing in GI and hepatobiliary malignancies, with expertise in the tumor immune microenvironment.

• Dr. Peter Hosein is a medical oncologist focused on GI cancers, leading clinical trials in immune targeting and stroma-modulating therapies.

Market insights and analysis

• Most pancreatic cancer patients present with advanced or metastatic disease, with a minority being resectable.

• Recent advances with RAS inhibitors, such as divarasib, represent a paradigm shift, but resistance remains a major unmet need.

• The tumor microenvironment, particularly the dense stroma and myeloid biology, is a key driver of resistance and a focus for new therapies.

• PDAC remains highly treatment-refractory, but new approaches targeting the RAS pathway and IL1RAP are emerging.

• The IL-1/IL1RAP axis is recognized as a key mediator of the immunosuppressive PDAC microenvironment.